GlassScriptPhysician profile
William Mcginty Mcbride
NPI 1497893325
$2,663.54
in general payments reported to CMS, 2019-2025
33 companies · $255 in 2025
The $255 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $455 · 2021: $523 · 2022: $396 · 2023: $412 · 2024: $341 · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,008.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $511.57 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $376.99 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $267.13 | 2020-2024 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $222.11 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $183.47 | 2019-2024 | Xifaxan, Trulance |
| Abbvie INC. | $122.81 | 2021-2023 | |
| Amgen INC. | $120.46 | 2019-2024 | Repatha, Evenity, Prolia |
| Pfizer INC. | $117.67 | 2020-2025 | |
| Abbott Laboratories | $85.99 | 2021-2024 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $81.20 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.98 | 2019-2024 | Ofev |
| Eisai INC. | $40.80 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.45 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $35.89 | 2022-2023 | Quviviq |
| Corcept Therapeutics | $32.45 | 2023-2025 | Korlym |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $31.83 | 2020 | |
| Xeris Pharmaceuticals, INC. | $31.06 | 2024 | Gvoke Hypopen |
| Astellas Pharma US INC | $29.94 | 2023-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $29.19 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.75 | 2021 | |
| Novartis Pharmaceuticals Corporation | $27.61 | 2019-2021 | |
| Averitas Pharma INC. | $22.42 | 2025 | Qutenza |
| Exact Sciences Corporation | $18.96 | 2025 | Cologuard Collection Kit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.10 | 2019 | |
| Sunovion Pharmaceuticals INC. | $17.52 | 2022 | |
| Bausch Health US, LLC | $16.92 | 2022 | |
| Medtronic, INC. | $16.67 | 2023 | Inpen Smart Insulin Delivery System |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.27 | 2024 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $15.81 | 2021 | |
| Zyla Life Sciences, INC. | $14.93 | 2020 | |
| Evoke Pharma, INC. | $14.61 | 2023 | Gimoti |
| Endo Pharmaceuticals INC. | $11.70 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mcbride listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.